Montalban-Bravo, Guillermo
Class, Caleb A. http://orcid.org/0000-0003-3130-3613
Ganan-Gomez, Irene
Kanagal-Shamanna, Rashmi
Sasaki, Koji
Richard-Carpentier, Guillaume
Naqvi, Kiran
Wei, Yue
Yang, Hui
Soltysiak, Kelly A.
Chien, Kelly
Bueso-Ramos, Carlos
Do, Kim-Anh
Kantarjian, Hagop
Garcia-Manero, Guillermo
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672, CA016672)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
University of Texas MD Anderson Cancer Center MDS/AML Moon Shot
Article History
Received: 29 March 2019
Revised: 17 October 2019
Accepted: 3 November 2019
First Online: 12 November 2019
Compliance with ethical standards
:
: HK declares research support and an advisory role with Actinium, and research support from AbbVie, Agio, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis, and Pfizer. GG-M declares research support and an advisory role with Amphivena, Astex, and Celgene, and research support from AbbVie, H3 Biomedicine, Helsin, Onconova, Merck, and Novartis. The other authors declare that they have no conflict of interest.